Status | Study |
NOT_YET_RECRUITING |
Study Name: Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2023-09-20 Interventions: Given PO |
RECRUITING |
Study Name: Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2023-07-26 Interventions: Given PO |
RECRUITING |
Study Name: A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2023-03-15 Interventions: Participants will receive treatment with intravenous tafasitamab and oral lenalidomide for up to 12 cycles.Each cycle is 28 days in length. |
RECRUITING |
Study Name: Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients Condition: Mantle Cell Lymphoma Date: 2022-09-01 Interventions: Given by PO |
COMPLETED |
Study Name: The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2017-09-25 Interventions: The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered for six 28-day cycles: bendamustine (90 mg/m2; (or 70mg/m2 for do |
Not yet recruiting |
Study Name: The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2016-10-11 Interventions: Drug: Bortezomib Bortezomib(V) |
Recruiting |
Study Name: Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2016-07-19 Interventions: Drug: Bortezomib, Cytarabine, Dexamethasone, Pegteograstim |
Withdrawn |
Study Name: A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2016-04-08 Interventions: Drug: acalabrutinib Drug: ibrutinib |
Recruiting |
Study Name: Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2015-02-02 Interventions: Drug: Ibrutinib |
Active, not recruiting |
Study Name: A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma Condition: Mantle Cell Lymphoma Date: 2013-01-24 Interventions: Drug: Bendamustine 90 mg/m2 ad |